Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GCTKNASDAQ:NVIVNASDAQ:TTOONASDAQ:VERO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGCTKGlucoTrack$0.15+2.5%$0.21$0.13▼$62.60$3.83M-0.142.25 million shs5.76 million shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsTTOOT2 Biosystems$0.17+12.8%$0.12$0.06▼$6.80$3.53M0.46607,455 shs111,148 shsVEROVenus Concept$2.43-4.0%$3.06$2.16▼$17.49$3.46M-0.03382,239 shs227,816 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGCTKGlucoTrack+2.47%-12.00%-12.00%-71.06%-99.73%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%TTOOT2 Biosystems+15.55%+4.94%+41.69%+157.52%-95.96%VEROVenus Concept-3.95%+3.85%-35.20%-34.04%-65.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGCTKGlucoTrack0.8591 of 5 stars0.03.00.00.02.61.70.6NVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/AN/AN/AN/AVEROVenus Concept0.8939 of 5 stars0.02.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGCTKGlucoTrack 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/ATTOOT2 Biosystems 2.00Hold$5.002,877.96% UpsideVEROVenus Concept 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGCTKGlucoTrackN/AN/AN/AN/A$15.30 per shareN/ANVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ATTOOT2 Biosystems$7.68M0.46N/AN/A($6.91) per share-0.02VEROVenus Concept$64.83M0.05N/AN/A($2.43) per share-1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGCTKGlucoTrack-$7.10M-$56.60N/A∞N/AN/A-826.43%-707.26%5/21/2025 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ATTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%7/28/2025 (Estimated)VEROVenus Concept-$37.25M-$77.35N/A∞N/A-74.62%N/A-47.46%5/15/2025 (Estimated)Latest NVIV, GCTK, VERO, and TTOO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GCTKGlucoTrackN/A-$0.34N/A-$0.67N/AN/A3/31/2025Q4 2024VEROVenus Concept-$10.0089-$11.23-$1.2211-$11.23$16.99 million$15.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGCTKGlucoTrackN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGCTKGlucoTrackN/A0.140.14NVIVInVivo TherapeuticsN/A14.3014.30TTOOT2 BiosystemsN/A0.400.24VEROVenus Concept2.831.861.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGCTKGlucoTrack10.92%NVIVInVivo Therapeutics13.78%TTOOT2 Biosystems23.18%VEROVenus Concept87.41%Insider OwnershipCompanyInsider OwnershipGCTKGlucoTrack46.50%NVIVInVivo Therapeutics2.45%TTOOT2 Biosystems0.03%VEROVenus Concept48.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGCTKGlucoTrack525.59 million5.57 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableVEROVenus Concept4101.42 million3.70 millionNot OptionableNVIV, GCTK, VERO, and TTOO HeadlinesRecent News About These CompaniesVenus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common StockApril 14, 2025 | globenewswire.comVenus Concept prices 386,700 shares at $4.06 in registered direct offeringApril 11, 2025 | markets.businessinsider.comVenus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 11, 2025 | globenewswire.comVenus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 10, 2025 | globenewswire.comVenus Concept to sell 328,573 shares at $3.50 in registered direct offeringApril 9, 2025 | markets.businessinsider.comVenus Concept Shares Tripled On Wednesday: Here's What HappenedApril 9, 2025 | benzinga.comVenus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 9, 2025 | globenewswire.comVenus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 9, 2025 | globenewswire.comVenus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025April 7, 2025 | globenewswire.comVenus Concept announces $11M debt-to-equity exchange transactionApril 2, 2025 | markets.businessinsider.comVenus Concept Completes Debt-to-Equity Exchange with MadrynApril 2, 2025 | tipranks.comVenus Concept Announces $11 million Debt-to-Equity Exchange TransactionApril 1, 2025 | globenewswire.comVenus Concept Inc. (NASDAQ:VERO) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVenus Concept reports Q4 EPS ($11.23) vs ($20.14) last yearApril 1, 2025 | markets.businessinsider.comVenus concept signals revenue stabilization as strategic shifts concludeMarch 31, 2025 | msn.comVenus Concept Inc. (VERO) Q4 2024 Earnings Conference Call TranscriptMarch 31, 2025 | seekingalpha.comVenus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 31, 2025 | globenewswire.com5VERO : Earnings Outlook For Venus ConceptMarch 28, 2025 | benzinga.comVenus Concept Inc trading halted, news pendingMarch 4, 2025 | markets.businessinsider.comVenus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025March 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVIV, GCTK, VERO, and TTOO Company DescriptionsGlucoTrack NASDAQ:GCTK$0.15 +0.00 (+2.47%) As of 05/14/2025 04:00 PM EasternGlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.T2 Biosystems NASDAQ:TTOO$0.17 +0.02 (+12.76%) As of 05/14/2025 03:58 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Venus Concept NASDAQ:VERO$2.43 -0.10 (-3.95%) As of 05/14/2025 04:00 PM EasternVenus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
